Therapeutic options for relapsed/refractory mantle cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma subtype.
• Standard frontline therapies include immunochemotherapy and autologous stem cell transplantation.
• Patients with MCL frequently relapse, necessitating effective subsequent treatment strategies.

Purpose of the Study:

• To review key therapeutic approaches for relapsed MCL.
• To discuss the role of covalent Bruton tyrosine kinase (BTK) inhibitors in relapsed MCL.
• To explore emerging therapies for patients progressing after BTK inhibition.

Main Methods:

• Literature review of therapeutic strategies for relapsed MCL.
• In-depth analysis of data supporting covalent BTK inhibitors.
• Discussion of resistance mechanisms and alternative treatments.

Main Results:

• Covalent BTK inhibitors demonstrate efficacy in relapsed MCL.
• Mechanisms of resistance to covalent BTK inhibitors are identified.
• Novel therapies including CAR T-cell therapy and noncovalent BTK inhibitors show promise.

Conclusions:

• Treatment decisions for relapsed MCL depend on various factors including patient status and therapy availability.
• Emerging therapies offer new hope for patients with relapsed or refractory MCL.
• Continued research into novel agents is crucial for improving outcomes in MCL.